27.10.2020
В. М. Цветов; Ю. Ю. Киселёв; К. Б. Мирзаев; Д. А. Сычёв
aminodihydrophthalazindione in «cytokine storm», including in patients with COVID-19. Protocols of planned or ongoing clinical
27.10.2020
К. А. Загородникова; К. Б. Мирзаев; Д. А. Сычёв
27.10.2020
В. А. Отделенов; В. М. Цветов; Д. А. Сычёв
with COVID-19 cannot be recommended.
27.10.2020
В. М. Цветов; К. Б. Мирзаев; Д. А. Сычёв
Routine clinical use of riamilovir in COVID-19 is not recommended. The use of riamilovir
27.10.2020
В. А. Отделенов; К. Б. Мирзаев; Д. А. Сычёв
Hospitalized patients with COVID-19 who have not previously received DOAK by it is not advisable
27.10.2020
К. Б. Мирзаев; Ю. Ю. Киселёв; Д. А. Сычёв
distress-syndrome in COVID-19, including combined use with tocilizumab, has been identified. Systemic
27.10.2020
А. В. Матвеев; В. А. Отделенов; Д. А. Сычёв
No scientific evidence for the negative influence of angiotensin II receptor blockers onto COVID-19
27.10.2020
Ю. Ю. Киселёв; К. Б. Мирзаев; Д. А. Сычёв
of acute respiratory distress-syndrome in patients with COVID-19, and such treatment is not supported
27.10.2020
А. В. Матвеев; Ю. Ю. Киселёв; Д. А. Сычёв
No published trials measuring effectiveness of tofacitinib in COVID-19 have been identified. Some
27.10.2020
В. М. Цветов; И. Н. Сычёв; Д. А. Сычёв
used in COVID-19. In this publication, the most important pharmacokinetic parameters and dose
